2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram M, Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open 2019, 2: e192589. PMID: 31002323, PMCID: PMC6481456, DOI: 10.1001/jamanetworkopen.2019.2589.Peer-Reviewed Original ResearchConceptsMinimally symptomatic metastatic castration-resistant prostate cancerSipuleucel-TProstate cancerSymptomatic metastatic castration-resistant prostate cancerDatabase of commercially insured patientsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAge of patientsRetrospective cohort studyFactors associated with useAssociated with patientsCommercially insured patientsPatterns of treatmentConcurrent therapyTreated patientsCohort studyMultivariate analysisCancer therapyTherapyPatientsPhysician factorsCancerBarriers to treatmentBinomial logistic regressionLogistic regression
2017
Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).
Oh W, Kandadi H, Sheikh N, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2017, 35: 36-36. DOI: 10.1200/jco.2017.35.7_suppl.36.Peer-Reviewed Original ResearchMinimally symptomatic metastatic castration-resistant prostate cancerOverall survivalPeripheral bloodSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerBaseline prostate-specific antigen levelBlood-based predictive biomarkersPredictive of OS benefitProstate-specific antigen levelCastration-resistant prostate cancerMultivariate Cox proportional hazards regression modelsImmunotherapy sipuleucel-TPB mononuclear cellsAssociated with OSPredictive of OSCox proportional hazards regression modelsFDA-approved immunotherapyProportional hazards regression modelsGene expressionHazards regression modelsGene expression signaturesAssociation of gene expressionMedian OSSipuleucel-TOS benefit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply